MAPT and Alzheimer disease: To date, the most accepted laboratory method for AD diagnosis in biofluids from living patients is the measurement of amyloid-β (1–42), total tau (T-tau), and phospho-tau-181 (P-tau181) in CSF, collected by lumbar punctures [80].